Drug intelligence / Profile preview

Qingxin Lotus Seed Granules

Development stage: Unknown
Lead developer: Yunnan Baiyao
Administration: Oral

Overview

PZ-018 (Qingxin Lotus Seed Granules) is a Traditional Chinese Medicine (TCM) candidate developed by Yunnan Baiyao Group. It is classified as a Category 3.1 new TCM, a regulatory pathway in China for modern formulations derived from ancient classic prescriptions. The drug is based on the "Qingxin Lianzi Yin" formula, which traditionally contains ingredients such as lotus seed, scutellaria, ginseng, and astragalus. It is intended for the treatment of symptoms associated with "heart-fire" and "damp-heat" patterns, including urinary frequency, turbid urine, and restlessness. As of 2024, the program has completed production validation and is in the process of drafting the NDA dossier for submission to the NMPA.

Other names: PZ-018PZ018PZ 018清心莲子颗粒Qingxin Lianzi Granules

Beyond the preview

Go deeper on Qingxin Lotus Seed Granules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Qingxin Lotus Seed Granules.

Explore the full profile